Federal Register of Legislation - Australian Government

Primary content

PB 83 of 2011 Lists as made
This instrument amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010) to make changes to the pharmaceutical benefits listed on the Pharmaceutical Benefits Scheme and related matters.
Administered by: Health
Registered 28 Nov 2011
Tabling HistoryDate
Tabled HR07-Feb-2012
Tabled Senate07-Feb-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 83 of 2011

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011
(No.12)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 22 November 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 12).

            (2)        This Instrument may also be cited as PB 83 of 2011.

2          Commencement

            This Instrument commences on 1 December 2011.

3          Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)

            Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).



Schedule 1     Amendments

 

[1]           Subsections 5(2), 5(3) and 5(4), and notes to 5(2) and 5(4)

substitute

(2)        For subparagraph 85(2)(b)(i) of the Act, paragraph 85(2)(b) of the Act applies to a listed drug mentioned in subparagraph (1)(a)(ii).

(3)        For subparagraph 85(2)(b)(ii) of the Act, paragraph 85(2)(b) of the Act applies to an additive mentioned in Part 2 of Schedule 2.

            Note           Part VII of the Act applies to medicinal preparations composed of 1 or more listed drugs mentioned in subsection (2) and 1 or more of the additives mentioned in subsection (3) – see paragraph 85(2)(b) of the Act.

[2]           Subsection 20(1), and note to subsection 20(1)

substitute:

(1)        For subsection 85 (2A) of the Act, if the letter D is mentioned in the column headed ‘Section 100 only’ in Schedule 1 for a listed drug, the drug can only be supplied under special arrangements under section 100 of the Act.

 

[3]           Schedule 1, entry for Alendronic Acid in the form Tablet 70 mg (as alendronate sodium)

omit from the column headed “Circumstances” (all instances):

C2645

insert in numerical order:

C3933

[4]           Schedule 1, entry for Alendronic acid with colecalciferol

omit from the column headed “Circumstances” (all instances):

C2645

insert in numerical order:

C3933

[5]           Schedule 1, entry for Alendronic acid with colecalciferol and calcium

omit from the column headed “Circumstances” (twice occurring):

C2645

insert in numerical order:

C3933

[6]           Schedule 1, entry for Arsenic

substitute:

Arsenic

Injection concentrate containing arsenic trioxide 10 mg in 10 mL

Injection

Phenasen

PL

MP

See Note 1

C3150 C3891

 

See Note 3

See Note 3

D

[7]           Schedule 1, after entry for Artemether with lumefantrine in the form Tablet (dispersible) 20 mg-120 mg

insert:

Asenapine

Sublingual wafer 5 mg (as maleate)

Sublingual

Saphris

LU

MP NP

C1589 C3935 C3936

 

60

5

 

 

Sublingual wafer 10 mg (as maleate)

Sublingual

Saphris

LU

MP NP

C1589 C3935 C3936

 

60

5

 

[8]           Schedule 1, entry for Bevacizumab

substitute:

Bevacizumab

Solution for I.V. infusion 100 mg in 4 mL

Injection

Avastin

RO

MP

See Note 1

C3430 C3431 C3894 C3896

 

See Note 3

See Note 3

D

 

Solution for I.V. infusion 400 mg in 16 mL

Injection

Avastin

RO

MP

See Note 1

C3430 C3431 C3894 C3896

 

See Note 3

See Note 3

D

[9]           Schedule 1, entry for Bisoprolol in each of the forms: Tablet containing bisoprolol fumarate 2.5 mg; Tablet containing bisoprolol fumarate 5 mg; and Tablet containing bisoprolol fumarate 10 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Bisoprolol GH

GQ

MP NP

C3234

 

28

5

 

[10]         Schedule 1, entry for Bleomycin

substitute:

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

Hospira Pty Limited

HH

MP

See Note 1

C1139 C1198

 

See Note 3

See Note 3

D

[11]         Schedule 1, entry for Bortezomib

substitute:

Bortezomib

Powder for injection 3.5 mg (with any determined brand of sodium chloride injection as the required solvent)

Injection

Velcade

JC

MP

See Note 1

C3762 C3763 C3764 C3765 C3766 C3767

P3764 P3767 See Note 2

4

See Note 2

2

See Note 2

 

 

 

 

 

 

MP

See Note 1

C3762 C3763 C3764 C3765 C3766 C3767

P3762 P3763 P3765 P3766

See Note 2

4

See Note 2

3

See Note 2

 

[12]         Schedule 1, entry for Botulinum Toxin Type Apurified Neurotoxin Complex

substitute:

Botulinum Toxin Type A Purified Neurotoxin Complex

Lyophilised powder for injection 100 units

Injection

Botox

AG

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[13]         Schedule 1, entry for Budesonide with Eformoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

insert in numerical order in the column headed “Circumstances”:

C2680

[14]         Schedule 1, entry for Capecitabine

omit from the column headed “Circumstances” (twice occurring):

C2267

insert in numerical order:

C3942


[15]         Schedule 1, entry for Captopril in each of the forms: Tablet 25 mg; and Tablet 50 mg

omit:

 

 

 

Ascent Pharma Pty Ltd

GM

MP NP

 

 

90

5

 

[16]         Schedule 1, entry for Carboplatin

substitute:

Carboplatin

Solution for I.V. injection 50 mg in 5 mL

Injection

Carboplatin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection 150 mg in 15 mL

Injection

Carboplatin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection 450 mg in 45 mL

Injection

Carboplatin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 


[17]         Schedule 1, entry for Cetuximab

substitute:

Cetuximab

Solution for I.V. infusion 100 mg in 20 mL

Injection

Erbitux

SG

MP

See Note 1

C2713 C2714 C2715 C3843 C3844 C3903 C3904 C3919 C3920 C3921

See Note 3

See Note 3

See Note 3

D

 

Solution for I.V. infusion 500 mg in 100 mL

Injection

Erbitux

SG

MP

See Note 1

C2713 C2714 C2715 C3843 C3844 C3903 C3904 C3919 C3920 C3921

See Note 3

See Note 3

See Note 3

D

[18]         Schedule 1, entry for Cisplatin

substitute:

Cisplatin

I.V. injection 10 mg in 10 mL

Injection

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

I.V. injection 50 mg in 50 mL

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

I.V. injection 100 mg in 100 mL

Injection

Cisplatin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 


[19]         Schedule 1, entry for Cladribine

substitute:

Cladribine

Injection 10 mg in 5 mL

Injection

Litak

OA

MP

See Note 1

C3180

 

See Note 3

See Note 3

D

 

Solution for I.V. infusion 10 mg in 10 mL single use vial

Injection

Leustatin

JC

MP

See Note 1

C3180

 

See Note 3

See Note 3

D

[20]         Schedule 1, entry for Codeine with Paracetamol

(a)        omit:

 

 

 

Dolaforte

CO

MP NP PDP

 

 

20

0

 

(b)        omit:

 

 

 

Dolaforte

CO

MP NP

 

P2064

60

0

 

[21]         Schedule 1, after entry for Colestipol

insert in the columns in the order indicated:

Corifollitropin Alfa

Solution for injection 100 micrograms in 0.5 mL single dose pre-filled syringe

Injection

Elonva

MK

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Solution for injection 150 micrograms in 0.5 mL single dose pre-filled syringe

Injection

Elonva

MK

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 


[22]         Schedule 1, entry for Cyclophosphamide

substitute:

Cyclophosphamide

Tablet 50 mg

Oral

Cycloblastin

PF

MP

 

 

 

50

2

 

 

Powder for injection 500 mg (anhydrous)

Injection

Endoxan

BX

MP

See Note 1

 

 

See Note 3

See Note 3

PB

 

Powder for injection 1 g (anhydrous)

Injection

Endoxan

BX

MP

See Note 1

 

 

See Note 3

See Note 3

PB

 

Powder for injection 2 g (anhydrous)

Injection

Endoxan

BX

MP

See Note 1

 

 

See Note 3

See Note 3

PB

[23]         Schedule 1, entry for Cytarabine

substitute:

Cytarabine

Injection 100 mg in 5 mL vial

Injection

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

[24]         Schedule 1, entry for Dalteparin

omit:

 

Injection containing dalteparin sodium 7,500 I.U. (anti-Xa) in 0.75 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

MP NP

 

P1148

20

3

 

 

Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

substitute:

 

Injection containing dalteparin sodium 7,500 I.U. (anti-Xa) in 0.75 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

MP NP

 

P1148

20

3

 

 

 

 

 

 

 

 

P3688

30

5

 

 

Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

 

 

P3688

30

5

 

 

Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

 

 

10

1

 

 

 

 

 

 

 

 

P3688

30

5

 

 

Injection containing dalteparin sodium 15,000 I.U. (anti-Xa) in 0.6 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

C3688

 

30

5

 

 

Injection containing dalteparin sodium 18,000 I.U. (anti-Xa) in 0.72 mL single dose pre-filled syringe

Injection

Fragmin

PF

MP NP

C3688

 

30

5

 

[25]         Schedule 1, after entry for Darunavir in the form Tablet 300 mg (as ethanolate)

insert in the columns in the order indicated:

 

Tablet 400 mg (as ethanolate)

Oral

Prezista

JC

MP
See Note 1

C3940 C3941

 

120

5

D

[26]         Schedule 1, after entry for Denosumab in the form Injection 60 mg in 1 mL pre-filled syringe

insert in the columns in the order indicated:

 

Injection 120 mg in 1.7 mL

Injection

Xgeva

AN

MP NP

C1035 C3881

 

1

5

 

[27]         Schedule 1, entry for Dexamethasone in the form Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Dexmethsone

AS

MP NP

 

 

5

0

 

 


[28]         Schedule 1, entry for Dexamethasone in the form Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Dexmethsone

AS

MP NP

 

 

5

1

 

[29]         Schedule 1, entry for Diltiazem in each of the forms: Capsule (controlled delivery) containing diltiazem hydrochoride 180 mg; and
Capsule (controlled delivery) containing diltiazem hydrochoride 240 mg

omit:

 

 

 

Dilzem CD

GM

MP NP

 

 

30

5

 

[30]         Schedule 1, entry for Docetaxel

substitute:

Docetaxel

Solution concentrate for I.V. infusion 140 mg in 7 mL

Injection

Oncotaxel 140

TA

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 160 mg in 16 mL

Injection

DBL Docetaxel Concentrated Injection

HH

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 20 mg with solvent

Injection

Docetaxel SUN

ZF

MP

See Note 1

C3186 C3884 C3890 C3893

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 80 mg with solvent

Injection

Docetaxel SUN

ZF

MP

See Note 1

C3186 C3884 C3890 C3893

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 20 mg in 1 mL

Injection

Oncotaxel 20

TA

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

See Note 3

See Note 3

See Note 3

D

 

 

 

Taxotere

SW

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

See Note 3

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 20 mg in 2 mL

Injection

DBL Docetaxel Concentrated Injection

HH

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916 C3918

See Note 3

See Note 3

See Note 3

D

 

 

 

Docetaxel Ebewe

HX

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916

See Note 3

See Note 3

See Note 3

D

 

 

 

Docetaxel Sandoz

SZ

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916 C3918

See Note 3

See Note 3

See Note 3

D

 

Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL with solvent

Injection

Taxotere

SW

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

See Note 3

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 80 mg in 4 mL

Injection

Oncotaxel 80

TA

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

 

 

Taxotere

SW

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 80 mg in 8 mL

Injection

DBL Docetaxel Concentrated Injection

HH

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

 

 

Docetaxel Ebewe

HX

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916

 

See Note 3

See Note 3

D

 

 

 

Docetaxel Sandoz

SZ

MP

See Note 1

C3186 C3884 C3888 C3890 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 

Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent

Injection

Taxotere

SW

MP

See Note 1

C3186 C3884 C3888 C3890 C3892 C3893 C3916 C3918

 

See Note 3

See Note 3

D

 


[31]         Schedule 1, entry for Doxorubicin

substitute:

Doxorubicin

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial

Injection/ intravesical

Adriamycin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Doxorubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial

Injection/ intravesical

Adriamycin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial

Injection/ intravesical

Adriamycin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Doxorubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 100 mg in 50 mL single dose vial

Injection/ intravesical

Doxorubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial

Injection/ intravesical

Adriamycin

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Doxorubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 


[32]         Schedule 1, entry for Doxorubicin ─ Pegylated Liposomal

substitute:

Doxorubicin – Pegylated Liposomal

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL

Injection

Caelyx

JC

MP

See Note 1

C1568 C1795 C1796 C3905 C3910 C3911

 

See Note 3

See Note 3

D

 

 

 

 

 

MP

See Note 1

C1828 C1829 C3348 C3349

 

4

5

D

 

Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL

Injection

Caelyx

JC

MP

See Note 1

C1568 C1795 C1796 C3905 C3910 C3911

 

See Note 3

See Note 3

D

[33]         Schedule 1, entry for Epirubicin

substitute:

Epirubicin

Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL

Injection/

intravesical

Epirubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pharmorubicin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL

Injection/

intravesical

Pharmorubicin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL

Injection/

intravesical

Epirubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pharmorubicin Solution

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

Injection/

intravesical

Epirubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL

Injection/

intravesical

DBL Epirubicin Hydrochloride Injection

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Epirubicin Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 


[34]         Schedule 1, entry for Etoposide

substitute:

Etoposide

Capsule 50 mg

Oral

Vepesid

BQ

MP

 

 

 

20

 

0

 

 

 

Capsule 100 mg

Oral

Vepesid

BQ

MP

 

 

 

10

 

0

 

 

 

Solution for I.V. infusion 100 mg in 5 mL vial

Injection

Etoposide Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

PB

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

PB

 

Powder for I.V. infusion 100 mg (as phosphate)

Injection

Etopophos

BQ

MP

See Note 1

 

 

See Note 3

See Note 3

PB

 

Powder for I.V. infusion 1 g (as phosphate)

Injection

Etopophos

BQ

MP

See Note 1

 

 

See Note 3

See Note 3

PB

[35]         Schedule 1, entry for Famciclovir

omit:

 

Tablet 500 mg

Oral

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Favic 500

QA

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Ezovir

AF

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Favic 500

QA

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

substitute:

 

Tablet 500 mg

Oral

APO-Famciclovir

TX

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Chem mart Famciclovir

CH

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Favic 500

QA

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Terry White Chemists Famciclovir

TW

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

APO-Famciclovir

TX

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Chem mart Famciclovir

CH

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Ezovir

AF

MP NP

C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Favic 500

QA

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Terry White Chemists Famciclovir

TW

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 


[36]         Schedule 1, entry for Fludarabine

substitute:

Fludarabine

Tablet containing fludarabine phosphate 10 mg

Oral

Fludara

GZ

MP

C3015

 

20

5

 

 

Powder for I.V. injection containing fludarabine phosphate 50 mg

Injection

Farine

WQ

MP

See Note 1

C3887

 

See Note 3

See Note 3

PB

 

 

 

Fludara

GZ

MP

See Note 1

C3887

 

See Note 3

See Note 3

PB

 

 

 

Fludarabine Actavis

TA

MP

See Note 1

C3887

 

See Note 3

See Note 3

PB

 

Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL

Injection

Fludarabine Ebewe

SZ

MP

See Note 1

C3887

 

See Note 3

See Note 3

PB

[37]         Schedule 1, entry for Fluorouracil

substitute:

Fluorouracil

Injection 500 mg in 10 mL

Injection

Fluorouracil Ebewe

SZ

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Injection 1000 mg in 20 mL

Injection

DBL Fluorouracil Injection BP

HH

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

 

 

Fluorouracil Ebewe

SZ

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Injection 2500 mg in 50 mL

Injection

DBL Fluorouracil Injection BP

HH

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

 

 

Fluorouracil Ebewe

SZ

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 

Injection 5000 mg in 100 mL

Injection

Fluorouracil Ebewe

SZ

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

 


[38]         Schedule 1, entry for Fotemustine

substitute:

Fotemustine

Powder for injection 208 mg with solvent

Injection

Muphoran

SE

MP

See Note 1

C3181

 

See Note 3

See Note 3

D

[39]         Schedule 1, entry for Ganirelix

omit (second instance):

 

 

 

Orgalutran

MK

MP

See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

D

[40]         Schedule 1, entry for Gemcitabine

substitute:

Gemcitabine

Powder for I.V. infusion 200 mg (as hydrochloride)

Injection

DBL Gemcitabine for Injection

HH

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Actavis

TA

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Ebewe

SZ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Kabi

PK

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Sun

ZF

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcite

ZP

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemplan

WQ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemzar

LY

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL

Injection

Gemcitabine Ebewe

SZ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 500 mg (as hydrochloride) in 50 mL

Injection

Gemcitabine Ebewe

SZ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 1 g (as hydrochloride)

Injection

DBL Gemcitabine for Injection

HH

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Actavis

TA

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Ebewe

SZ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Kabi

PK

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Sun

ZF

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcite

ZP

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemplan

WQ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemzar

LY

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL

Injection

Gemcitabine Ebewe

SZ

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 2 g (as hydrochloride)

Injection

DBL Gemcitabine for Injection

HH

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 

 

 

Gemcitabine Kabi

PK

MP

See Note 1

C1193 C1194 C1740 C2069 C2141 C3889 C3890 C3906 C3913 C3914

 

See Note 3

See Note 3

D

 


[41]         Schedule 1, entry for Idarubicin

substitute:

Idarubicin

Capsule containing idarubicin hydrochloride 5 mg

Oral

Zavedos

PF

MP

 

C1006

 

3

0

 

 

Capsule containing idarubicin hydrochloride 10 mg

Oral

Zavedos

PF

MP

 

C1006

 

3

0

 

 

Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL

Injection

Idarubicin Ebewe

SZ

MP

See Note 1

C1006

 

See Note 3

See Note 3

PB

 

 

 

Zavedos Solution

PF

MP

See Note 1

C1006

 

See Note 3

See Note 3

PB

 

Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL

Injection

Idarubicin Ebewe

SZ

MP

See Note 1

C1006

 

See Note 3

See Note 3

PB

 

 

 

Zavedos Solution

PF

MP

See Note 1

C1006

 

See Note 3

See Note 3

PB

[42]         Schedule 1, entry for Ifosfamide

substitute:

Ifosfamide

Powder for I.V. injection 1 g in single dose vial

Injection

Holoxan

BX

MP

See Note 1

C1325 C1327

 

See Note 3

See Note 3

D

 

Powder for I.V. injection 2 g in single dose vial

Injection

Holoxan

BX

MP

See Note 1

C1325 C1327

 

See Note 3

See Note 3

D

[43]         Schedule 1, after entry for Imiquimod

insert:

Indacaterol

Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler)

Inhalation by mouth

Onbrez

NV

MP NP

C3883

 

30

5

 

 

Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler)

Inhalation by mouth

Onbrez

NV

MP NP

C3883

 

30

5

 

 


[44]         Schedule 1, entry for Interferon Alfa-2a

substitute:

Interferon Alfa-2a

Injection 3,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

Roferon-A

RO

MP

See Note 1

C1149 C1196 C1234 C3180 C3895 C3899

P1149 P1234

P3180 P3899

15

 

4

 

 

 

 

 

 

 

MP

See Note 1

C1149 C1196 C1234 C3180 C3895 C3899

P1196 P3895

 

15

 

5

 

 

 

 

 

 

 

MP
See Note 1

C1463 C3382 C3869 C3870

 

30

5

 

C

 

Injection 4,500,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

Roferon-A

RO

MP

See Note 1

C1196 C1234 C3895 C3899

P1234 P3899

 

5

 

4

 

 

 

 

 

 

 

MP

See Note 1

C1196 C1234 C3895 C3899

P1196 P3895

5

5

 

 

 

 

 

 

MP
See Note 1

C1463 C3382 C3869 C3870

 

30

5

C

 

Injection 6,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

Roferon-A

RO

MP

See Note 1

C1196 C1234 C3895 C3899

P1234 P3899

5

4

 

 

 

 

 

 

MP

See Note 1

C1196 C1234 C3895 C3899

P1196 P3895

5

5

 

 

 

 

 

 

MP
See Note 1

C1463 C3382 C3869 C3870

 

30

 

5

C

 

Injection 9,000,000 I.U. in 0.5 mL single dose pre-filled syringe

Injection

Roferon-A

RO

MP

See Note 1

C1196 C1234 C3895 C3899

P1234 P3899

5

4

 

 

 

 

 

 

MP

See Note 1

C1196 C1234 C3895 C3899

P1196 P3895

5

5

 

 

 

 

 

 

MP
See Note 1

C1463 C3382 C3869 C3870

 

30

5

C

[45]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 18,000,000 I.U.in 1.2 mL multi-dose injection pen

omit:

 

 

 

 

 

MP

See Note 1

C1149 C1196 C1206

P1149

3

4

 

 

 

 

 

 

MP

See Note 1

C1149 C1196 C1206

P1196 P1206

3

5

 

substitute:

 

 

 

 

 

MP

See Note 1

C1149 C1196 C1206 C3180 C3895 C3898

P1149 P3180

3

4

 

 

 

 

 

 

MP

See Note 1

C1149 C1196 C1206 C3180 C3895 C3898

P1196 P1206 P3895 P3898

3

5

 

[46]         Schedule 1, entry for Interferon Alfa-2b in the form Solution for injection 30,000,000 I.U. in 1.2 mL multi-dose injection pen

omit:

 

 

 

 

 

MP

See Note 1

C1196 C1206

 

3

5

 

substitute:

 

 

 

 

 

MP

See Note 1

C1196 C1206 C3895 C3898

 

3

5

 

[47]         Schedule 1, entry for Irinotecan

substitute:

Irinotecan

I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL

Injection

Camptosar

PF

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Actavis

TA

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Alphapharm

AF

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Ebewe

SZ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Kabi

PK

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Omegapharm Irinotecan

OE

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Tecan

WQ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL

Injection

Camptosar

PF

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Hospira Pty Limited

HH

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Actavis

TA

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Alphapharm

AF

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Ebewe

SZ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Kabi

PK

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Omegapharm Irinotecan

OE

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Tecan

WQ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

I.V. injection containing irinotecan hydrochloride trihydrate 300 mg in 15 mL

Injection

Camptosar

PF

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Ebewe

SZ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL

Injection

Hospira Pty Limited

HH

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Actavis 500

TA

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

 

 

 

Irinotecan Ebewe

SZ

MP

See Note 1

C3184

 

See Note 3

See Note 3

D

[48]         Schedule 1, entry for Lacosamide

omit:

 

Oral solution 15 mg per mL, 200 mL

Oral

Vimpat

UC

MP NP

C3303 C3304

 

2

5

 

 


[49]         Schedule 1, after entry for Lopinavir with Ritonavir

insert:

Losartan

Tablet containing losartan potassium 25 mg

Oral

Cozavan

AF

MP NP

 

 

30

5

 

 

Tablet containing losartan potassium 50 mg

Oral

Cozavan

AF

MP NP

 

 

60

5

 

[50]         Schedule 1, after entry for Macrogol 3350 in the form Powder for oral solution 510 g [your pharmacy Clear Laxative (third instance)]

insert:

Magnesium

Tablet 37.4 mg (as aspartate dihydrate)

Oral

Mag-Sup

PP

MP NP

C3937 C3938

 

50

5

 

[51]         Schedule 1, entry for Medroxyprogesterone in the form Tablet containing medroxyprogesterone acetate 10 mg

(a)        omit from the column headed “Responsible Person”:                 SZ          substitute:             HX

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Medroxyprogesterone Sandoz

SZ

MP NP

 

 

30

2

 

[52]         Schedule 1, entry for Metformin in the form Tablet containing metformin hydrochloride 500 mg

omit:

 

 

 

Glucohexal

HX

MP NP

 

 

100

5

 

[53]         Schedule 1, entry for Metformin in the form Tablet containing metformin hydrochloride 850 mg

omit:

 

 

 

Glucohexal

HX

MP NP

 

 

60

5

 

[54]         Schedule 1, entry for Metformin in the form Tablet containing metformin hydrochloride 1 g

omit:

 

 

 

Glucohexal

HX

MP NP

 

 

90

5

 

 


[55]         Schedule 1, entry for Methotrexate

substitute:

Methotrexate

Tablet 2.5 mg

Oral

Hospira Pty Limited

HH

MP

 

 

30

5

 

 

 

 

Methoblastin

PF

MP

 

 

30

5

 

 

Tablet 10 mg

Oral

Methoblastin

PF

MP

 

 

15

3

 

 

 

 

 

 

MP

 

P2884

50

2

 

 

Injection 5 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

See Note 2

5

See Note 2

0

See Note 2

 

 

Injection 50 mg in 2 mL vial

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

See Note 2

5

See Note 2

5

See Note 2

 

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

See Note 2

5

See Note 2

5

See Note 2

 

 

Solution concentrate for I.V. infusion 500 mg in 20 mL vial

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 1000 mg in 10 mL vial

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

 

 

Methotrexate Ebewe

SZ

MP

See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 

Solution concentrate for I.V. infusion 5000 mg in 50 mL vial

Injection

Methotrexate Ebewe

SZ

MP

See Note 1

 

See Note 3

See Note 3

See Note 3

PB

 


[56]         Schedule 1, entry for Mitozantrone

substitute:

Mitozantrone

Injection 10 mg (as hydrochloride) in 5 mL

Injection

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Injection 20 mg (as hydrochloride) in 10 mL

Injection

Hospira Pty Limited

HH

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Mitozantrone Ebewe

SZ

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Onkotrone

BX

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

Injection 25 mg (as hydrochloride) in 12.5 mL

Injection

Onkotrone

BX

MP

See Note 1

 

 

See Note 3

See Note 3

D

 

 

 

Pfizer Australia Pty Ltd

PF

MP

See Note 1

 

 

See Note 3

See Note 3

D

[57]         Schedule 1, entry for Morphine in each of the forms: Tablet containing morphine sulfate 10 mg (controlled release); Tablet containing morphine sulfate 30 mg (controlled release); Tablet containing morphine sulfate 60 mg (controlled release); and Tablet containing morphine sulfate 100 mg (controlled release)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

APOTEX-MORPHINE MR

TX

MP NP

C1062

 

28

0

 

[58]         Schedule 1, entry for Nafarelin

substitute:

Nafarelin

Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses

Nasal

Synarel

PF

MP

See Note 1

C1172 C1389

See Note 2

See Note 2

1

See Note 2

5

See Note 2

 

 


[59]         Schedule 1, entry for Norethisterone with Ethinyloestradiol in the form Pack containing 12 tablets 500 micrograms-35 micrograms,
9 tablets 1 mg-35 micrograms and 7 inert tablets

omit:

 

 

 

Synphasic

PF

MP NP

 

 

4

2

 

[60]         Schedule 1, entry for Norethisterone with Mestranol

substitute:

Norethisterone with Mestranol

Pack containing 21 tablets 1 mg-50 micrograms and 7 inert tablets

Oral

Norinyl-1/28

PF

MP NP

 

 

4

2

 

[61]         Schedule 1, entry for Oxaliplatin

substitute:

Oxaliplatin

Solution concentrate for I.V. infusion 50 mg in 10 mL

Injection

DBL Oxaliplatin Concentrate

HH

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Eloxatin

SW

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Kabi

PK

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin SUN

ZF

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 50 mg

Injection

Hospira Pty Limited

HH

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxalatin

ZP

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Actavis

TA

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Alphapharm

AF

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Ebewe

SZ

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Link

PK

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Xalox

WQ

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 100 mg in 20 mL

Injection

DBL Oxaliplatin Concentrate

HH

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Eloxatin

SW

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Kabi

PK

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin SUN

ZF

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

Powder for I.V. infusion 100 mg

Injection

Hospira Pty Limited

HH

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxalatin

ZP

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Actavis

TA

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Alphapharm

AF

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Ebewe

SZ

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin Link

PK

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Winthrop Oxaliplatin

WA

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Xalox

WQ

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

Solution concentrate for I.V. infusion 200 mg in 40 mL

Injection

Eloxatin

SW

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 

 

 

Oxaliplatin SUN

ZF

MP

See Note 1

C3900 C3901 C3930 C3939

 

See Note 3

See Note 3

D

 


[62]         Schedule 1, after entry for Oxycodone in the form Suppository 30 mg (as pectinate)

insert:

Oxycodone with naloxone

Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg

Oral

Targin 5/2.5mg

MF

MP NP

C1062

 

28

0

 

 

Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg

Oral

Targin 10/5mg

MF

MP NP

C1062

 

28

0

 

 

Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg

Oral

Targin 20/10mg

MF

MP NP

C1062

 

28

0

 

 

Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg

Oral

Targin 40/20mg

MF

MP NP

C1062

 

28

0

 

[63]         Schedule 1, entry for Paclitaxel

substitute:

Paclitaxel

Solution concentrate for I.V. infusion 30 mg in 5 mL

Injection

Anzatax

HH

MP

See Note 1

C3186 C3890 C3893 C3902 C3917 C3918

 

See Note 3

See Note 3

D

 

 

 

Paclitaxel Actavis

TA

MP

See Note 1

C3186 C3890 C3893 C3902 C3917 C3918

 

See Note 3

See Note 3